×

MODIFIED RELEASE FORMULATION AND METHODS OF USE

  • US 20100120906A1
  • Filed: 07/17/2009
  • Published: 05/13/2010
  • Est. Priority Date: 07/18/2008
  • Status: Abandoned Application
First Claim
Patent Images

1. A modified release pharmaceutical formulation, comprising:

  • about 30-70% N-(2-amino-4-(fluorobenzylamino)-phenyl)carbamic acid ethyl ester (retigabine), or a pharmaceutically acceptable salt, solvate or hydrate thereof;

    about 5-30% of a drug delivery matrix comprising hydroxypropylmethylcellulose (HPMC),about 1.0-10% of an anionic surfactant andan enteric polymer,said pharmaceutical formulation producing a sustained plasma concentration of said retigabine following administration to a subject for 4-20 hours longer than the time required for in vitro release of 80% of said retigabine.

View all claims
  • 5 Assignments
Timeline View
Assignment View
    ×
    ×